CorMedix

CRMD

Market cap $564M

CorMedix is entering a post-TDAPA reset, with DefenCath revenue expected to decline materially and no proven second growth engine in place. FY26 guidance of ~$310M (midpoint) masks underlying deceleration, as DefenCath declines from $258.8M in FY25 to $150M–$170M in FY26, with the year-end run rate likely materially weaker heading into FY27. Rezzayo and DefenCath TPN offer long-term optionality but lack current financial contribution, while Melinta provides stability rather than growth.

PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming 25th Annual Needham Virtual Healthcare Conference taking place April 13 – 16, 2026.

CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript

CorMedix (CRMD) came out with quarterly earnings of $0.61 per share, missing the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.22 per share a year ago.

‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒   ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J.

BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time.

CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.

CorMedix heads into Q4 earnings with DefenCath sales, Melinta product contributions, and its muted 2026 guidance firmly in focus.

CRMD stock sinks 27% in 3 months as its bearish 2026 outlook for DefenCath clouds near-term growth, raising investor concern.

CorMedix Inc. (CRMD) Analyst/Investor Day Transcript